Overview

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Adrenergic Agonists
Solabegron